Marksans Pharma Pregabalin Capsules get USFDA okay

Published On 2022-07-22 06:27 GMT   |   Update On 2022-07-22 07:21 GMT
Advertisement

Mumbai: Marksans Pharma Limited has announced that the company has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Lyrica Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg, of Upjohn US 2 LLC.

Advertisement

The medicine is indicated in relieving pain resulting from nerve damage because of diabetes, shingles, spinal cord injury, or other conditions.

Pregabalin capsules (RLD Lyrica) had estimated annual sales of USD 263 million in the U.S. (IQVIA MAT March 2022).

Read also: Marksans Pharma to acquire 100 percent stake in Access Healthcare for Rs 27 crore

Marksans Pharma, headquartered at Mumbai (India) is a global pharmaceutical company.

The company's key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, Gynaecology, among others.

Read also: Marksans Pharma gets UK MHRA nod for Bells Healthcare All in One Oral Solution






Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News